文献速递泌尿男性生殖肿瘤

尿液DNA甲基化检测用于膀胱癌诊断

Urinary DNA Methylation Test for Bladder Cancer Diagnosis.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项前瞻性多中心研究在韩国10个中心纳入1099例40岁以上血尿患者,评估尿液DNA甲基化检测(PENK甲基化)对高级别或浸润性膀胱癌的诊断效能,并与NMP22检测或尿细胞学比较。结果显示该检测对高级别或浸润性膀胱癌灵敏度89.2%、特异度87.8%,对总体膀胱癌灵敏度78.1%、特异度88.8%,灵敏度显著优于NMP22检测或尿细胞学。

要点

  • 尿液DNA甲基化检测对高级别或浸润性膀胱癌灵敏度89.2%、特异度87.8%。
  • 对总体膀胱癌灵敏度78.1%、特异度88.8%。
  • 阴性预测值97.6%,阳性预测值61.3%。

核心结论

  • 在血尿人群中,尿液DNA甲基化检测对高级别或浸润性膀胱癌显示89%的灵敏度,以高特异度优于NMP22检测或尿细胞学,阴性预测值优秀但阳性预测值欠佳。

研究设计与样本

  • 前瞻性多中心研究,在韩国10个中心开展,纳入2022年3月11日至2024年5月30日期间3个月内接受膀胱镜检查的40岁及以上血尿个体。
  • 共纳入1099例参与者,614例(55.9%)为男性,平均(SD)年龄65(10)岁。
  • 219例患有膀胱癌,176例患有高级别或浸润性膀胱癌。

主要发现

  • 尿液DNA甲基化检测对高级别或浸润性膀胱癌的灵敏度为89.2%(95%CI,84.6%-93.8%),特异度为87.8%(95%CI,85.6%-89.9%)。
  • 对总体膀胱癌(所有分期和分级)的灵敏度为78.1%(95%CI,72.6%-83.6%),特异度为88.8%(95%CI,86.7%-90.8%)。
  • 对高级别或浸润性膀胱癌的阳性预测值为61.3%(95%CI,55.4%-67.3%),阴性预测值为97.6%(95%CI,96.6%-98.7%)。
  • 与NMP22检测或尿细胞学检测相比,尿液DNA甲基化检测对高级别或浸润性膀胱癌及总体膀胱癌的灵敏度显著更优。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: An accurate noninvasive biomarker test is needed for the early diagnosis of bladder cancer. OBJECTIVE: To evaluate the performance of a urinary DNA methylation test (PENK methylation) and compare its diagnostic accuracy with that of the nuclear matrix protein 22 (NMP22) test or urine cytology test. DESIGN, SETTING, AND PARTICIPANTS: In this prospective multicenter study at 10 sites in the Republic of Korea, individuals 40 years and older with hematuria undergoing cystoscopy within 3 months between March 11, 2022, and May 30, 2024, participated. The study participants were evaluated for bladder cancer using a urinary DNA methylation test. EXPOSURE: Urinary DNA methylation test, NMP22 test, and urine cytology test. MAIN OUTCOMES AND MEASURES: The primary outcomes were the sensitivity and specificity of the urinary DNA methylation test for high-grade or invasive bladder cancer. Secondary objectives included the accuracy of the test for overall bladder cancer (all stages and grades) and the comparison of sensitivities and specificities for bladder cancer between the urinary DNA methylation test and the NMP22 test or urine cytology test. RESULTS: Among the 1099 participants, 614 (55.9%) were male; participants had a mean (SD) age of 65 (10) years. Of the 1099 participants, 219 and 176 participants had bladder cancer and high-grade or invasive bladder cancer, respectively. The urinary DNA methylation test had sensitivity and specificity for high-grade or invasive bladder cancer of 89.2% (95% CI, 84.6%-93.8%) and 87.8% (95% CI, 85.6%-89.9%), respectively. Sensitivity and specificity for overall bladder cancer were 78.1% (95% CI, 72.6%-83.6%) and 88.8% (95% CI, 86.7%-90.8%), respectively. The positive predictive value for high-grade or invasive bladder cancer was 61.3% (95% CI, 55.4%-67.3%), and the negative predictive value was 97.6% (95% CI, 96.6%-98.7%). In comparison with the NMP22 test or urine cytology test, the urinary DNA methylation test showed significantly superior sensitivity for high-grade or invasive bladder cancer and overall bladder cancer. CONCLUSIONS AND RELEVANCE: In this prospective multicenter study of individuals with hematuria, the urinary DNA methylation test showed 89% sensitivity for detecting high-grade or invasive bladder cancer, outperforming the NMP22 test or urine cytology test with high specificity. While this test had an excellent negative predictive value, its positive predictive value was suboptimal.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Jeong IG, Yun SC, Ha HK, et al. Urinary DNA Methylation Test for Bladder Cancer Diagnosis. JAMA Oncol. 2025. PMID: 39883469. doi:10.1001/jamaoncol.2024.6160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。